How should I initiate guideline‑directed medical therapy for a patient with chronic heart failure with reduced ejection fraction, including management of congestion, symptom relief, and mortality reduction?

Heart Failure with Reduced Ejection Fraction: Guideline-Directed Medical Therapy Initiation

Initiate all four foundational medication classes simultaneously—SGLT2 inhibitor, mineralocorticoid receptor antagonist (MRA), beta-blocker, and ARNI (or ACE inhibitor if ARNI unavailable)—as soon as the diagnosis of HFrEF is confirmed, which provides approximately 73% mortality reduction over 2 years. 1

Immediate Congestion Management

Loop diuretics are the first priority for symptom relief in patients with fluid overload. 2

• Administer loop diuretics (furosemide, bumetanide, or torsemide) to all patients presenting with signs or symptoms of congestion—peripheral edema, pulmonary rales, elevated jugular venous pressure, or orthopnea 2
• Congestion drives heart failure hospitalizations and mortality regardless of ejection fraction 3
• Titrate diuretic dose based on daily weights, clinical examination findings, and symptom resolution 2
• Avoid excessive diuresis before initiating ACE inhibitors or ARNI, as volume depletion increases hypotension and acute kidney injury risk 2

Foundational Quadruple Therapy: Simultaneous Initiation

The contemporary approach abandons sequential therapy in favor of rapid, simultaneous initiation of all four medication classes 1:

1. SGLT2 Inhibitor (Start Immediately)

• Initiate dapagliflozin 10 mg daily or empagliflozin 10 mg daily regardless of diabetes status 1
• SGLT2 inhibitors reduce cardiovascular death and heart failure hospitalization with minimal blood pressure effect, allowing safe early initiation 1
• These agents provide natriuresis and reduce congestion independent of traditional diuretic mechanisms 4
• No titration required—therapeutic dose is the starting dose 1

2. Mineralocorticoid Receptor Antagonist (Start Immediately)

• Begin spironolactone 12.5-25 mg daily or eplerenone 25 mg daily 1
• MRAs provide at least 20% mortality reduction and decrease sudden cardiac death 1
• Minimal blood pressure effect permits early initiation alongside other agents 1
• Check potassium and creatinine at baseline, 1 week, and 1 month after initiation 2

3. Beta-Blocker (Start Immediately)

• Use only evidence-based agents: carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily, or bisoprolol 1.25 mg daily 2, 1
• Beta-blockers reduce mortality by at least 20% and decrease sudden cardiac death 1
• Titrate upward every 1-2 weeks to target doses: carvedilol 25-50 mg twice daily, metoprolol succinate 200 mg daily, or bisoprolol 10 mg daily 2, 1
• Start with low doses even in stable patients to minimize bradycardia and hypotension 2

4. ARNI or ACE Inhibitor (Start Immediately)

ARNI (sacubitril/valsartan) is strongly preferred over ACE inhibitors 1:

• Start sacubitril/valsartan 24 mg/26 mg twice daily (or 49 mg/51 mg twice daily if blood pressure tolerates) 1
• ARNI provides superior mortality reduction of at least 20% compared to ACE inhibitors 1
• Titrate to target dose of 97 mg/103 mg twice daily over 3-6 weeks 1
• Mandatory 36-hour washout period if switching from ACE inhibitor to avoid angioedema 1

If ARNI is unavailable or contraindicated, use ACE inhibitor:

• Start enalapril 2.5 mg twice daily, lisinopril 2.5-5 mg daily, or ramipril 1.25-2.5 mg daily 2
• Review and potentially reduce diuretic dose 24 hours before ACE inhibitor initiation 2
• Avoid NSAIDs and potassium-sparing diuretics during initiation 2
• Titrate to target doses proven in trials: enalapril 10-20 mg twice daily, lisinopril 20-40 mg daily, ramipril 5-10 mg daily 2

Titration Timeline and Monitoring

Uptitrate beta-blocker and ARNI/ACE inhibitor every 2-4 weeks to target maintenance doses 2:

• Check blood pressure, renal function (creatinine, eGFR), and electrolytes (potassium) at baseline 2
• Recheck 1-2 weeks after each medication adjustment 2
• Recheck at 3 months, then every 6 months during maintenance phase 2
• Target doses should be achieved within 6-12 weeks of diagnosis 5

Critical Contraindications and Drug Interactions

Never combine ACE inhibitor with ARB and MRA—this triad causes life-threatening hyperkalemia and renal dysfunction 2:

• Avoid diltiazem and verapamil entirely in HFrEF as they worsen heart failure and increase hospitalization risk 2
• ARNI is contraindicated with history of angioedema from prior ACE inhibitor or ARB therapy 1
• ARNI is contraindicated with concomitant ACE inhibitor or aliskiren use in diabetic patients 1

Device Therapy Timing

Reassess LVEF after 3 months of optimal medical therapy before device decisions 2:

• Implantable cardioverter-defibrillator (ICD) for primary prevention: LVEF ≤35% despite ≥3 months optimal medical therapy, NYHA Class II-III, expected survival >1 year 2, 1
• Do not implant ICD within 40 days of myocardial infarction—no survival benefit during this period 2
• Cardiac resynchronization therapy (CRT): Sinus rhythm with QRS ≥150 msec, left bundle branch block morphology, LVEF ≤35% despite optimal medical therapy 2, 1

Secondary Therapies for Persistent Symptoms

If symptoms persist despite optimal quadruple therapy and device consideration 5:

• Ivabradine: Add if heart rate ≥70 bpm on maximally tolerated beta-blocker dose, sinus rhythm only 5
• Hydralazine/isosorbide dinitrate: Add in Black patients for additional mortality benefit, or if ARNI/ACE inhibitor/ARB contraindicated 5
• Vericiguat: Consider if recent heart failure hospitalization or need for IV diuretics despite optimal therapy 5
• Digoxin: May reduce hospitalizations but does not reduce mortality; reserve for persistent symptoms 5

Special Populations

Severe renal impairment (eGFR <30 mL/min): Start ARNI at 24 mg/26 mg twice daily instead of higher dose 1

Iron deficiency (ferritin <100 ng/mL or ferritin 100-299 ng/mL with transferrin saturation <20%): Administer intravenous iron replacement to improve functional status and quality of life 5

Multidisciplinary Care Structure

Hospitalization for heart failure is an opportunity to initiate and optimize all four medication classes before discharge 6:

• Provide predischarge counseling with written instructions on medication schedule, daily weight monitoring, and follow-up appointments 6
• Schedule uptitration visits at 2-week intervals for the first 3 months 6
• Establish seamless transition between hospital, heart failure specialist, and primary care provider 6
• Patient education on self-care significantly increases adherence and reduces mortality and hospitalizations 6